XDC Academy

Antibody-Peptide Conjugates (APCs), riding the booming wave of global peptide therapeutics, harness antibodies’ precise targeting to deliver therapeutic peptides directly to diseased cells. Combining antibodies’ exquisite specificity with the potent pharmacological activity of therapeutic peptides, APCs complement conventional ADCs and standalone peptide modalities, opening new avenues for precision targeted therapy.

APCs deliver distinct value: addressing the short half-life, rapid renal clearance and poor stability of free peptides, while equipping antibody scaffolds with broader functional versatility and superior tissue penetration. This transformative edge positions APCs as a high-potential frontier in next-generation antibody-conjugated therapeutics.

This slide deck comprehensively covers APCs, including their mechanism of action, core advantages, competitive landscape, and WuXi XDC’s leading APC development capabilities and diverse bioconjugate services. It explores how WuXi XDC drives innovation via proprietary conjugation technologies and end-to-end services to accelerate progress in this fast-growing peptide-conjugate therapeutic field.